Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01827787 · ClinicalTrials.gov registry record · Phase 2
Eribulin in HER2 Negative Metastatic BrCa
A Phase 2 study of Breast Cancer, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
- 7
- Study locations
NCT01827787 is a Phase 2 study of Breast Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 83 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 7 study locations across 3 states.
The verdict
NCT01827787, a Phase 2 study of Breast Cancer, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
- 7
- Study locations
Study Summary
Improvements in outcomes with metastatic breast cancer (MBC) have been observed in the last 30 years, however, overall prognosis remains poor with median survival of 2 to 3 years. Long term complete responses are observed only for a minority of MBC patients (2-5%) and MBC remains an incurable disease for most patients. Eribulin is a chemotherapy approved by the US FDA in November of 2010 to treat patients with MBC who have received at least two prior chemotherapy regimens. In this research study, the investigators are looking to see how well eribulin helps participants with MBC in an earlier-line setting. Eribulin works by interfering with cancer cell division, growth and spread.
Conditions Studied
Interventions
- DRUG Eribulin
Study Locations (7)
Massachusetts
- Dana-Farber Cancer Institute at Faulkner Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
- DF/BWCC at Milford Regional Cancer Center - Milford
- South Shore Hospital - Weymouth
Maine
- Eastern Maine Medical Center - Bangor
New Hampshire
- Dana-Farber/New Hampshire Oncology-Hematology - Londonderry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2013-05 |
| Est. Completion | 2016-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01827787
The ClinicalTrials.gov registry entry for NCT01827787 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Eribulin is the first listed.
NCT01827787 reports 7 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Maine, New Hampshire.
Frequently Asked Questions
What is clinical trial NCT01827787 about?
NCT01827787 is a clinical study titled "Eribulin in HER2 Negative Metastatic BrCa". Improvements in outcomes with metastatic breast cancer (MBC) have been observed in the last 30 years, however, overall prognosis remains poor with median survival of 2 to 3 years. Long term complete responses are observed only for a minority of MBC patients (2-5%) and MBC remains an incurable diseas...
What is the current status of trial NCT01827787?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2013-05. Estimated completion is 2016-05.
What conditions does trial NCT01827787 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT01827787?
The interventions under investigation include: Eribulin (DRUG).
Who is sponsoring clinical trial NCT01827787?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01827787 being conducted?
This trial has 7 study locations across Maine, Massachusetts, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.